Abhilasha Singh: Lp(a) as a Long-Term Cardiovascular Risk Signal in Healthy Women
Abhilasha Singh, Review Editor at Frontiers in Stroke and Reviewer at Springer Nature Phytomedicine, shared on LinkedIn about a recent article by Ask Tybjærg Nordestgaard and et al, published in JAMA Cardiology:
“Lp(a): A 30-Year Cardiovascular Risk Signal We May Be Underestimating
A 30-year follow-up of ~27,000 initially healthy women (JAMA Cardiology, 2026) shows that elevated Lipoprotein(a) [Lp(a)] independently predicts long-term cardiovascular risk.
What the Data Show
- Lp(a) level of 30 mg/dL or higher is associated with an increased incidence of major adverse cardiovascular events.
- Lp(a) levels of 120 mg/dL or higher increase the risk of coronary heart disease, ischemic stroke, and cardiovascular death.
- Clear dose–response gradient
- Risk persists beyond traditional factors
- Lp(a) is largely genetically determined
Why This Matters Clinically
- Prevention remains centered on LDL-C
- Most 10-year risk models do not integrate Lp(a)
- ‘Normal cholesterol’ does not equal absence of inherited risk.
- Short-term prediction may miss lifelong exposure
Perspective
This study invites reconsideration of how we define and operationalize cardiovascular risk in the era of genomic medicine. ”
Title: Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)
Authors: Tybjærg Nordestgaard, Daniel I. Chasman, Vinayaga Moorthy, Jordan M. Kraaijenhof, Nancy R. Cook, I-Min Lee, Julie E. Buring, Paul M. Ridker
Read the Full Article on JAMA Cardiology .
Stay updated on all scientific advances with Hemostasis Today .
-
Sep 8, 2026, 02:49Jared Rice: High Platelets, Low Clot Risk? – What Makes Neonatal Platelets Different in Sepsis
-
Sep 8, 2026, 02:46Rasha E.: Exploring Polycythemia Vera: Beyond the Hematocrit
-
Sep 8, 2026, 02:35Ahmet Davut Aksu: Plasminogen Supplementation Enhances Alteplase Efficacy in Systemic Embolization Model
-
Sep 7, 2026, 23:56Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month